SCHEMBL15468253

SCHEMBL15468253

COc1cc(-c2nnc(OC)n2-c2cccc3ccccc23)c(O)cc1O

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HSP90AA1 P07900 1/20 0.40
HSP90AB1 P08238 1/20 0.40
KCNN4 O15554 1/20 0.40
HPGD P15428 2/20 0.39
MEN1 O00255 3/20 0.38
KMT2A Q03164 3/20 0.38
GAA P10253 2/20 0.38
ALDH1A1 P00352 3/20 0.37
MAPT P10636 4/20 0.36
TDP1 Q9NUW8 4/20 0.36
L3MBTL1 Q9Y468 2/20 0.36
SMN1; SMN2 Q16637 1/20 0.36
LMNA P02545 2/20 0.35
MAPK1 P28482 2/20 0.35
KDM4E B2RXH2 2/20 0.35
TSHR P16473 2/20 0.35
NR1I2 O75469 1/20 0.35
NR3C1 P04150 1/20 0.35
ADRB1 P08588 1/20 0.35
HTR1A P08908 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14286488 0.89 HSP90AA1 (0.40) HSP90AA1HSP90AB1KCNN4HPGDMEN1
SCHEMBL930673 0.88 SLC37A4 (0.37) HSP90AA1HSP90AB1KCNN4HPGDMEN1
SCHEMBL930691 0.88 MEN1 (0.36) HSP90AA1HSP90AB1KCNN4HPGDMEN1
SCHEMBL931234 0.87 HSP90AA1 (0.39) HSP90AA1HSP90AB1KCNN4HPGDMEN1
SCHEMBL931758 0.81 HCRTR1 (0.38) HSP90AA1HSP90AB1MEN1KMT2AALDH1A1
SCHEMBL930519 0.81 ALDH1A1 (0.40) HSP90AA1HSP90AB1MEN1KMT2AGAA
SCHEMBL8931074 0.79 HSP90AA1 (0.63) HSP90AA1HSP90AB1HPGDMEN1KMT2A
SCHEMBL1305613 0.77 GAA (0.39) HSP90AA1HSP90AB1HPGDMEN1KMT2A
SCHEMBL13639233 0.73 HSP90AA1 (0.62) HSP90AA1HSP90AB1HPGDMEN1KMT2A
SCHEMBL15468252 0.73 TUBB4A (0.40) HSP90AA1HSP90AB1HPGDMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8648104-B2 Method for treating proliferative disorders associated with mutations in c-Met SYNTA PHARMACEUTICALS CORP. (US) 2014-02-11 US disclosed